BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Fresenius Kabi AG Restricts Propofol Use for Executions


9/27/2012 8:16:33 AM

As a result of a campaign by activists to pressure drugmakers to prevent their medications from being used in the US for lethal injections, Fresenius Kabi recently adopted a new policy in which orders from any corrections officials for its Propofol drug will be rejected. Propofol is an anaesthetic that has been used for executions in the wake of shortages of other medications. The move is seen as significant because Fresenius is the sole supplier in the US. Late last month, the German drugmaker wrote a letter to healthcare providers to say that using Propofol for executions is “contrary to the FDA approved indications” and “inconsistent” with its “mission” and “objects to the use of its products in any manner that is not in full accordance with approved indications.” The August 28 letter, which was only disclosed publicy as of today, was signed by Scott Meacham, the chief commercial officer for Fresenius Kabi USA.

Read at Pharmalot
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->